Paula Tamashiro Tairaku, MD
Pediatrics · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Tairaku’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A176919 · Current
Licensed to practise in California · since 2022 · expires 2028-03-31 · University of San Martin of Porres Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatrics
Medicaid work
$47,167 in 2024
Medicaid paid $47,167 for 522 billed services this clinician did in 2024, up to 55 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 375 | $43,770 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 12 | $1,478 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 36 | $1,047 |
| Screening test, pure tone, air only | 46 | $861 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 12 | $9 |
| Bilateral quantitative screening test of visual acuity | 41 | $0 |
| 2024 | 522 | 6 | 55 | $47,167 |
| 2023 | 915 | 9 | 55 | $10,443 |
| 2022 | 360 | 6 | 59 | $1,940 |
| 2021 | 3,788 | 10 | 115 | $202,970 |
| 2020 | 3,919 | 8 | 92 | $178,487 |
| 2019 | 2,275 | 6 | 45 | $121,754 |
| 2018 | 341 | 4 | 38 | $22,346 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 438 | $8,401 |
| Screening test, pure tone, air only | 142 | $753 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 124 | $644 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 13 | $254 |
| Short return visit | 23 | $148 |
| Bilateral quantitative screening test of visual acuity | 109 | $125 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 12 | $84 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 17 | $34 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 37 | $0 |
2022
| Short return visit (20+ min) | 189 | $1,828 |
| Screening test, pure tone, air only | 27 | $42 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 48 | $28 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 17 | $24 |
| Bilateral quantitative screening test of visual acuity | 26 | $10 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 53 | $9 |
2021
| OFF/OP EST MAY X REQ PHY/QHP | 773 | $94,556 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 789 | $32,364 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 766 | $30,899 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 678 | $13,847 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 171 | $10,368 |
| Short return visit (20+ min) | 147 | $5,983 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 168 | $5,775 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 207 | $5,123 |
| SARSCOV CORONAVIRUS AG IA | 76 | $2,458 |
| Return visit (30+ min) | 13 | $1,597 |
2020
| Short return visit (20+ min) | 426 | $52,205 |
| OFF/OP EST MAY X REQ PHY/QHP | 395 | $41,203 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 1,725 | $32,111 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 509 | $19,626 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 102 | $12,735 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 494 | $10,863 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | 184 | $6,796 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 84 | $2,949 |
2019
| Short return visit (20+ min) | 427 | $51,457 |
| OFF/OP EST MAY X REQ PHY/QHP | 223 | $28,215 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 488 | $18,597 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 1,067 | $18,429 |
| Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A | 58 | $3,499 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 12 | $1,555 |
2018
| Short return visit (20+ min) | 90 | $10,975 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 225 | $8,426 |
| Return visit (30+ min) | 13 | $1,514 |
| OFF/OP EST MAY X REQ PHY/QHP | 13 | $1,432 |
Money from drug and device companies
$262 in 2022
A payment is not proof that care is biased.
| Baxter Healthcare | None | $262 | 1 payment
|
See the published payment
| Baxter Healthcare | Debt forgiveness · 2022-05-25 | None | $262 |
Professional record
- NPI
- 1184007486
- Licence
- CA A176919California A176919: Current · expires 2028-03-31
More record details
- Sole proprietor
- No
- Taxonomy
- Pediatrics (208000000X); Student in a training program (390200000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2015-07-04
- NPI last updated
- 2022-08-26
- NPI record certified
- 2022-08-26
This is when the NPI record was last certified, not a medical board exam.